1. Janssen Research and Development. Olysio™ (SMV): US prescribing information. http://www.olysio.com/shared/product/olysio/prescribing-information.pdf . Accessed 27 May 2015.
2. Ouwerkerk-Mahadevan S, Sekar V, Simion A, et al. The pharmacokinetic interactions of the HCV protease inhibitor SMV (TMC435) with HIV antiretroviral agents in healthy volunteers. Poster 1618 presented at the ID week; 17–21 Oct 2012; San Diego (CA).
3. Ouwerkerk-Mahadevan S, Snoeys J, Peeters M, et al. Drug–drug interactions with the NS3/4A protease inhibitor simeprevir. Clin Pharmacokinet. 2016;55(2):197–208.
4. Ouwerkerk-Mahadevan S, Snoeys J, Simion A, et al. A novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of SMV in healthy volunteers. Poster oral presentation presented at the 15th international workshop on clinical pharmacology of HIV and hepatitis therapy, 19–21 May 2014, Washington, DC.
5. Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology. 2010;138:913–21.